REM Products Inc.

CombinatoRx Reports Financial Results for the Third Quarter 2009.(Financial report)
Biotech Week; 11/18/2009; 1615 words; ...Committee on Exalgo and its REMS program, Sanofi-Aventis...Neuromed Pharmaceuticals Inc. The merger seeks to...bringing together the product assets and financial...CombinatoRx portfolio of product candidates and our unique...acquired by Mallinckrodt Inc., a subsidiary of ...

PPD Awarded U.S. Food and Drug Administration Contract to Evaluate FDA's Spontaneous Adverse Event Surveillance System.
Biotech Week; 11/11/2009; 983 words; PPD, Inc. (Nasdaq: PPDI) announced...public (see also PPD, Inc.). The award of $2...Collection throughout a Product's Life Cycle (IMPACT...risk management plans/REMS, pregnancy registries...Drug Administration, PPD Inc. This article was prepared...

GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010.
Business Wire; 11/10/2009; 1074 words; ...GSK) and XenoPort, Inc. (Nasdaq: XNPT) today...Mitigation Strategy (REMS) was necessary for GSK1838262...GSK submitted a proposed REMS. The FDA accepted this...internally discovered product candidates that utilize...partnership with Astellas Pharma Inc. and GSK. XenoPort...

Amgen Provides Update on Status of Prolia™ (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA).
Women's Health Weekly; 11/5/2009; 867 words; Amgen Inc. (NASDAQ:AMGN) announced...review of applications for product approval. The Complete...Mitigation Strategy (REMS) is necessary for Prolia...of assessments of the REMS. The FDA acknowledged...world. Keywords: Amgen Inc., Biologics, Biotechnology...

Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results.
PR Newswire; 11/5/2009; 4429 words; ...Savient Pharmaceuticals, Inc. today reported financial...Mitigation Strategy (REMS). -- Our requested...resubmission will include REMS materials, this is subject...overall demand for the product from increased generic...adjusted our Oxandrin product return reserve in both...